Vernakalant (Synonyms: RSD1235)

Cat. No.: HY-14182: Data Sheet Handling Instructions Technical Support

Vernakalant(RSD-1235) is an investigational mixed ion channel blocker that can terminate acute atrial fibrillation (AF) in humans at 2 to 5 mg/kg and may be more atrial-selective than available agents; in treatment of antiarrhythmic.

At equivalent molar concentrations, both the salt and free forms of a compound exhibit comparable biological activity. Nevertheless, the salt form (Vernakalant Hydrochloride) usually boasts enhanced water solubility and stability.

For research use only. We do not sell to patients.

Vernakalant Chemical Structure

CAS No. : 794466-70-9

Size		Stock
MOQ		Minimum order quantity
50 mg		Get quote
100 mg		Get quote
250 mg		Get quote
Other size		Get quote

* Please select Quantity before adding items.

Other In-stock Forms of Vernakalant:

Vernakalant Hydrochloride

Other Forms of Vernakalant:

Vernakalant Hydrochloride In-stock
Vernakalant-d₆ hydrochloride Get quote

3 Publications Citing Use of MCE Vernakalant

Featured Recommendations

•Related Small Molecules:

•Related Proteins:

Biological Activity
Purity & Documentation
References
Customer Review

Description

Clinical Trial

NCT Number	Sponsor	Condition	Start Date	Phase
NCT04748991	University of Calgary	Atrial Fibrillation\|Post-cardiac Surgery	January 2024	Phase 3
NCT00668759	Advanz Pharma	Atrial Fibrillation	April 2008	Phase 3
NCT00468767	Advanz Pharma\|Astellas Pharma US, Inc.	Atrial Fibrillation	August 2003	Phase 3
NCT01627106	Advanz Pharma	Atrial Fibrillation	September 2012	Phase 4
NCT00115791	Astellas Pharma Inc\|Advanz Pharma	Atrial Flutter\|Atrial Fibrillation	June 2004	Phase 3
NCT00476112	Advanz Pharma\|Astellas Pharma US, Inc.	Atrial Flutter	August 2003	Phase 2\|Phase 3
NCT00989001	Advanz Pharma	Atrial Fibrillation	October 2009	Phase 3
NCT01447862	Medical University of Vienna	Atrial Fibrillation	October 2011	Phase 4
NCT00125320	Astellas Pharma Inc\|Astellas Pharma US, Inc.\|Advanz Pharma	Atrial Fibrillation\|Atrial Flutter	June 2004	Phase 3
NCT01370629	Correvio International Sarl\|Advanz Pharma	Atrial Fibrillation	August 2011
NCT00267930	Advanz Pharma	Atrial Fibrillation	December 2005	Phase 2
NCT00281554	Astellas Pharma Inc\|Advanz Pharma	Atrial Fibrillation	October 2005	Phase 3
NCT01646281	Maastricht University Medical Center	Atrial Fibrillation	August 2012	Phase 4
NCT01174160	Advanz Pharma	Atrial Fibrillation	August 2010	Phase 3
NCT00526136	Advanz Pharma	Atrial Fibrillation	March 2007	Phase 2
NCT04485195	Ottawa Hospital Research Institute	Atrial Fibrillation	June 17, 2021	Phase 4
NCT03005366	David Filgueiras-Rama\|Fundación Centro Nacional de Investigaciones Cardiovasculares Carlos III\|Hospital San Carlos, Madrid	Paroxysmal Atrial Fibrillation	January 2017	Phase 4

Molecular Weight

349.46

Formula

C₂₀H₃₁NO₄

CAS No.

794466-70-9

SMILES

COC1=C(C=C(C=C1)CCO[C@H]2[C@@H](CCCC2)N3CC[C@H](C3)O)OC

Shipping

Room temperature in continental US; may vary elsewhere.

Storage

Please store the product under the recommended conditions in the Certificate of Analysis.

Purity & Documentation

Data Sheet (272 KB) Handling Instructions (2659 KB)

References

[1]. Dorian, Paul MD et al. The Effect of Vernakalant (RSD1235), an Investigational Antiarrhythmic Agent, on Atrial Electrophysiology in Humans. Journal of Cardiovascular Pharmacology:July 2007 - Volume 50 -Issue 1 - pp 35-40.

[2]. Jodene Eldstrom et al. The Molecular Basis of High-Affinity Binding of the Antiarrhythmic Compound Vernakalant (RSD1235) to Kv1.5 Channels. Molecular Pharmacology December 2007 vol. 72 no. 6 1522-1534

[3]. Vernakalant. Too dangerous in atrial fibrillation.Prescrire Int. 2012 May;21(127):119-22. [Content Brief]

[4]. Blomstr?m-Lundqvist C, Blomstr?m P.Safety and efficacy of pharmacological cardioversion of atrial fibrillation using intravenous vernakalant, a new antiarrhythmic drug with atrial selectivity.Expert Opin Drug Saf. 2012 Jul;11(4):671-9. Epub 2012 May 26. [Content Brief]

[5]. Bash LD, Buono JL, Davies GM, Martin A, Fahrbach K, Phatak H, Avetisyan R, Mwamburi M.Systematic review and meta-analysis of the efficacy of cardioversion by vernakalant and comparators in patients with atrial fibrillation.Cardiovasc Drugs Ther. 2012 Apr; [Content Brief]

Vernakalant Related Classifications

Cardiovascular Disease

Molarity Calculator
Dilution Calculator

The molarity calculator equation

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass		Concentration		Volume		Molecular Weight *
	=		×		×

The dilution calculator equation

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

This equation is commonly abbreviated as: C₁V₁ = C₂V₂

Concentration _(start)	×	Volume _(start)	=	Concentration _(final)	×	Volume _(final)
	×		=		×
C1		V1		C2		V2

Keywords:

Vernakalant794466-70-9RSD1235RSD 1235RSD-1235Potassium ChannelKcsAInhibitorinhibitorinhibit

Your Recently Viewed Products:

Product Name

Requested Quantity *

Applicant Name *

Salutation

Email Address *

Phone Number *

Department

Organization Name *

City

State

Country or Region *

Remarks

Product Name

Lot #

Applicant Name *

Email Address *

Phone Number

Department *